deaths (OS)progression or deaths (PFS)RFS/DFS

laNSCLC - M - all population locally advanced NSCLC - maintenance (M) laNSCLC - M - all population

versus placebo
durvalumab alone vs. placebo 1 certainty unassessablestatistically conclusive-29% certainty unassessablestatistically conclusive-44%-